870
ANTI-MICROBIOTA SYSTEMIC IGG DEPLETES PROTECTIVE BUTYRATE-PRODUCING COMMENSALS IN IBD AND LONG PRECEDES CROHN’S DISEASE ONSET
Date
May 20, 2024
Tracks
Related Products
NATURAL HISTORY OF PRESUMED ISOLATED CROHN'S DISEASE PERIANAL FISTULA
Approximately 20% of patients with Crohn’s disease (CD) have perianal fistulizing CD, which are most often complex perianal fistula (PAF). Studies have shown that 4-5% of patients with CD present with PAF without luminal disease, termed isolated perianal CD (iPCD)…
CHARACTERIZING EPITOPES AND ISOTYPES OF CROHN'S DISEASE-ASSOCIATED ANTI-GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR ANTIBODIES.
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) maintains mononuclear phagocytes (MNP) and supports intestinal immune homeostasis. Anti-GM-CSF autoantibodies (aGMAbs) are found in approx. 25% of all Crohn’s disease (CD) patients…
DISABILITY IN CROHN'S DISEASE PATIENTS AT DIAGNOSIS: FINDINGS FROM THE CROCO (CROHN'S DISEASE COHORT) STUDY
BACKGROUND: Crohn's disease (CD) can lead to progressive bowel damage and disability. Disability has been proposed by the SPIRIT-IOIBD consensus as an endpoint in disease-modification trials. Despite this, there is scarce data on disability at CD diagnosis…
DECIPHERING THE POTENTIAL CRITICAL LINK BETWEEN VIRUSES AND GM-CSF AUTOANTIBODIES IN PREDICTING CROHN'S DISEASE COMPLICATIONS
Anti-granulocyte/macrophage-colony stimulating factor autoantibody (GM-CSF AuAB) has been identified before the onset of Crohn’s Disease (CD) and is associated with an increase in complicated disease. However, its connection to the gut microbiome, a key factor in CD progression, remains unclear…




